Vitamin E and PUFA Combination for NAFLD Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) lack effective hepatoprotective agents with minimal side effects, and existing therapies do not adequately address the underlying inflammatory and oxidative stress mechanisms contributing to excessive fat accumulation in the liver.
Innovation Solution
A combination of vitamin E and polyunsaturated fatty acids (PUFAs) in specific weight ratios, used in medicaments or nutraceutical compositions, modulates the biosynthesis and overproduction of inflammatory mediators, providing hepatoprotective effects and reducing liver inflammation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If vitamin E and PUFAs are used in combination to treat NAFLD, then hepatoprotective effects and anti-inflammatory activity are improved, but the complexity of the treatment regimen increases
Solution Approach 1:
The patent combines vitamin E and PUFAs into a single pharmaceutical composition that can be administered together, merging two separate therapeutic agents into one unified treatment formulation. This approach maintains the synergistic hepatoprotective effects while simplifying the administration regimen compared to separate treatments.
Solution Approach 2:
The invention creates a composite pharmaceutical composition containing both vitamin E and PUFAs in specific ratios, utilizing the complementary properties of these two substances to achieve enhanced therapeutic effects. The composite formulation leverages the antioxidant properties of vitamin E alongside the anti-inflammatory properties of PUFAs to address multiple pathogenic mechanisms simultaneously.
2Reliability
If high doses of PUFAs are administered alone, then some therapeutic effect is achieved, but coagulation parameters are adversely affected
Solution Approach 1:
Vitamin E acts as a protective intermediary that mitigates the adverse coagulation effects of high-dose PUFAs. The antioxidant properties of vitamin E prevent oxidative modification of PUFAs that would otherwise interfere with coagulation pathways, allowing higher doses of PUFAs to be used therapeutically without the harmful coagulation disturbances.
Solution Approach 2:
The patent converts the potential harm of PUFA-induced coagulation disturbances into a benefit by using vitamin E to prevent oxidative stress. The combination allows the therapeutic anti-inflammatory effects of PUFAs to be maximized while the harmful coagulation effects are prevented through the protective action of vitamin E against oxidative modification.
3Reliability
If vitamin E is used alone to treat NASH, then some improvement in liver enzymes is achieved, but the treatment is not effective for diabetic patients with NASH
Solution Approach 1:
The combined composition of vitamin E and PUFAs creates a universal treatment that addresses multiple pathogenic mechanisms involved in NASH pathogenesis, including oxidative stress, inflammation, and lipid metabolism dysfunction. This multi-functional approach makes the treatment effective across different patient populations, including diabetic patients where monotherapy with vitamin E alone has failed.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The combination of vitamin E and PUFAs synergistically inhibits the production of pro-inflammatory cytokines and mediators, effectively preventing and treating NAFLD and related liver conditions by reducing liver inflammation and oxidative stress, with minimal side effects.
Implementation Method 1
modulates the biosynthesis and overproduction of inflammatory mediators
Implementation Method 2
reducing liver inflammation and oxidative stress
Implementation Method 3
An excess of these molecules depletes natural antioxidants such as glutathione and vitamin E in the liver, causing oxidative stress which results in lipid peroxidation
Data Source
AI summary
The present invention relates to the use of mixtures of vitamin E and polyunsaturated fatty acids (PUFAs) as agents for the prevention, control and/or treatment of conditions associated with excessive fat accumulation in the liver which is not caused by alcohol abuse. This includes prevention, control and/or treatment of non-alcoholic steatosis in the liver - known as non-alcoholic fatty liver disease (NAFLD) - and/or non-alcoholic steatohepatitis (NASH) in a subject in need thereof. In particular, the present invention relates to the use of such compounds comprising vitamin E and PUFAs as active ingredients in the manufacture of medicaments for the prevention, control and/or treatment of conditions related to NAFLD.